528583-91-7

Usage

Uses

Used in Pharmaceutical Applications:
7S,8R,17R-Trihydroxy-4Z,9E,11E,13Z,15E19Z-Docosahexaenoic acid is used as a therapeutic agent for its anti-inflammatory and immunomodulatory properties. It has been shown to exhibit a dose-dependent reduction in leukocyte infiltration, which can be beneficial in managing inflammatory conditions.
Used in Predictive Medicine:
In the field of predictive medicine, 7S,8R,17R-Trihydroxy-4Z,9E,11E,13Z,15E19Z-Docosahexaenoic acid is used as a biomarker for predicting patient response to disease-modifying antirheumatic drugs (DMARDs). Its ability to modulate immune responses and reduce inflammation makes it a valuable tool in assessing the effectiveness of DMARDs in patients with autoimmune diseases such as rheumatoid arthritis.
Used in Nutritional Supplements:
7S,8R,17R-Trihydroxy-4Z,9E,11E,13Z,15E19Z-Docosahexaenoic acid can be used as an ingredient in nutritional supplements, particularly those aimed at supporting brain health, cognitive function, and cardiovascular health. Its omega-3 fatty acid base and unique molecular structure contribute to its potential benefits in these areas.
Used in Cosmetics:
In the cosmetics industry, 7S,8R,17R-Trihydroxy-4Z,9E,11E,13Z,15E19Z-Docosahexaenoic acid may be used as an active ingredient in skincare products due to its anti-inflammatory and skin-protective properties. It could potentially be used to soothe and repair damaged skin, as well as to improve skin hydration and overall health.
Used in Research and Development:
Due to its unique structure and biological activities, 7S,8R,17R-Trihydroxy-4Z,9E,11E,13Z,15E19Z-Docosahexaenoic acid is also used in research and development for the discovery of new drugs and therapies. Its potential applications in various fields, including pharmaceuticals, nutrition, and cosmetics, make it an interesting compound for further investigation and development.

Upstream product

• 127268-92-2 (S,Z)-1-((2S,3S)-3-(trimethylsilyl)oxiran-2-yl)hex-3-en-1-ol 
• 937738-64-2 methyl (4Z,7S,8R,9E,11E,13Z,15E,17R,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoate 
• 1415668-64-2 methyl (Z)-6-((4S,5R)-5-((1E,3E)-hexa-1,3-dien-5-yn-1-yl)-2,2-dimethyl-1,3-dioxolan-4-yl)hex-4-enoate 
• 1221440-60-3 (3RS,1E,5Z)-1-iodoocta-1,5-diene-3-ol 

Relevant academic research and scientific papers

Stereocontrolled synthesis of resolvin D1

We studied the synthesis of RvD1, a pro-resolving mediator. The intermediate containing vic-diol and enal functional groups was prepared via the oxidation of the γ,δ-epoxy alcohol followed by the epoxide ring opening in one pot. The C11-aldehyde in the resulting enal was converted to the trans iodo-olefin by reaction with TMSC(N2)Li and subsequent hydrozirconation using in situ generated Cp2Zr(H)Cl followed by iodination. The trans enynyl alcohol was synthesized by the reaction of the TMS-containing epoxy alcohol with lithium TMS-acetylide. Finally, two fragments were joined by the Sonogashira coupling, and the triple bond was reduced to afford RvD1 stereoselectively.

Total synthesis of Resolvin D1, a potent anti-inflammatory lipid mediator

The total synthesis of Resolvin D1, a potent endogenous anti-inflammatory lipid mediator derived from docosahexaenoic acid, has been achieved. The chiral hydroxy-groups at C7, C8 and C17 were obtained via a chiral pool strategy from 2-deoxy-d-ribose. Witt

COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION

The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.

USE OF DOCOSATRIENES, RESOLVINS AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA

The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful ;isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.